Curis Prices Public Offering of Common Stock
February 25, 2015 08:08 ET
|
Curis, Inc.
LEXINGTON, Mass., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), announced today the pricing of an underwritten registered public offering of 21,818,181 shares of its common stock at a...
Curis Announces Proposed Public Offering of Common Stock
February 24, 2015 16:02 ET
|
Curis, Inc.
LEXINGTON, Mass., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), announced today that it has commenced an underwritten public offering of shares of its common stock. In connection with...
Curis Reports Fourth Quarter and Year-End 2014 Financial Results
February 24, 2015 16:00 ET
|
Curis, Inc.
LEXINGTON, Mass., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...
Curis to Present at the 2015 Bio CEO and Investor Conference
February 03, 2015 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Curis and Aurigene Announce Collaboration, License and Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno-Oncology and Precision Oncology Targets
January 21, 2015 06:05 ET
|
Curis, Inc.
-- Agreement Provides Curis with Option to Exclusively License Aurigene's Antagonists for Immuno-Oncology, Including an Antagonist of PD-L1 and Selected Precision Oncology Targets, Including an...
Curis Announces Dosing of First Patient in Phase 1 Trial of CUDC-907 in Patients With Advanced/ Relapsed Solid Tumors
December 18, 2014 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Curis to Present at Upcoming Investor Conferences
November 26, 2014 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., Nov. 26, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Curis to Present at the Stifel 2014 Healthcare Conference
November 12, 2014 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Curis Reports Third Quarter 2014 Financial Results and Pipeline Update
November 10, 2014 07:00 ET
|
Curis, Inc.
-- Curis Provides Summary From Dose Escalation Stage of CUDC-907 Phase 1 Study Supporting Ongoing Expansion in DLBCL Patients –
-- Curis Expects to Regain Rights to Debio 0932; Debiopharm...
Curis to Release Third Quarter 2014 Financial Results and Hold Conference Call on November 10, 2014
November 03, 2014 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced that the...